Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Oragenics Inc. Common Stock (NY:OGEN)

0.4851 +0.0071 (+1.49%)
Streaming Delayed Price Updated: 1:40 PM EDT, Sep 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Oragenics Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
BioMedNewsBreaks — Oragenics, Inc. (NYSE American: OGEN) Reports on Lead Candidate Drug Development, ‘Urgency’ to Advance First-in-Class Concussion Treatment
Via Investor Brand Network
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Advances Concussion Treatment with Promising Study for Nasal Spray Drug ONP-002
Via Investor Brand Network
News headline image
EXCLUSIVE: Oragenics Completes Key FDA-Recognized Study For Concussion Drug Candidate ↗
Oragenics completed a key study showing its nasal spray drug ONP-002 effectively targets brain-related nasal areas, setting the stage for Phase 2 trials in concussion treatment. 
Via Benzinga
News headline image
Why DocuSign Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Why Oragenics (OGEN) Stock Is Getting Hammered ↗
Oragenics shares are trading lower by 47% during Wednesday's session. The company announced a $4.45 million public offering. 
Via Benzinga
News headline image
OGEN Stock Earnings: Oragenics Reported Results for Q2 2024 ↗
Oragenics just reported results for the second quarter of 2024. 
Via InvestorPlace
News headline image
OGEN Stock Earnings: Oragenics Reported Results for Q4 2023 ↗
Oragenics just reported results for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Closes on $4.45M Public Offering
Via Investor Brand Network
BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Enters into Public Offering Agreement Estimated to Total $4.45M
Via Investor Brand Network
News headline image
Why Oragenics (OGEN) Shares Are Falling ↗
Oragenics shares are trading lower by 21% during Tuesday's session. The company announced pricing of its public offering. 
Via Benzinga
News headline image
OGEN Stock Earnings: Oragenics Reported Results for Q1 2024 ↗
Oragenics just reported results for the first quarter of 2024. 
Via InvestorPlace
News headline image
Crude Oil Down 1%; Dollar Tree Shares Tumble After Downbeat Earnings ↗
 
Via Benzinga
News headline image
US Stocks Mixed; Trade Gap Widens In July ↗
 
Via Benzinga
News headline image
Why GitLab Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Completes Manufacture, Filling of Intranasal Device for Use in Upcoming Clinical Trial
Via Investor Brand Network
News headline image
EXCLUSIVE: Oragenics Completes Spray Dry Drug Manufacturing, Intranasal Device Filling For Anticipated Mid-Stage Study For Patients With Brain Injury ↗
Oragenics completes the formulation and filling of its nasal spray drug, ONP-002, for concussion treatment, aiming to launch a Phase 2a trial. 
Via Benzinga
BioMedNewsBreaks — Oragenics Inc. (NYSE American: OGEN) Reports on Status of Lead Drug Candidate Designed to Treat Concussion
Via Investor Brand Network
“Explosive Growth Stocks: Innovations, Strategy, Earners Unlock Prime Potential CXAI, OGEN, PRSO, INBS, KAVL”
Via AB Newswire
Topics Artificial Intelligence
News headline image
As Traumatic Brain Injuries Increase, Global Concussion Market Size Expected to Reach $10 Billion By 2032
EQNX::TICKER_START (NYSE:OGEN),(NYSE:ABT),(NASDAQ:BIIB),(NYSE:PFE),(NYSE:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
EXCLUSIVE: Oragenics' Concussion Drug Clears FDA-Required Cardiotoxicity Testing, Planning For Phase Trials Underway ↗
Oragenics announced its lead candidate, ONP-002, for treating concussion, which shows no cardiotoxicity in studies. Designed for nasal delivery to the brain, ONP-002 aims to address the significant... 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗
Pre-market stock movers are worth checking out on Tuesday as we get into all of the hottest news worth reading about this morning! 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Nasdaq Falls Over 100 Points; TJX Posts Upbeat Q1 Results ↗
 
Via Benzinga
News headline image
Why XP Shares Are Trading Lower By Around 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Gold Down Over 1%; Williams-Sonoma Posts Strong Earnings ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.